NCT06251076 Plan Development for Giving Teclistamab in the Outpatient Setting
| NCT ID | NCT06251076 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University Health Network, Toronto |
| Condition | Multiple Myeloma |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-11-19 |
| Primary Completion | 2026-06-15 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.
Eligibility Criteria
Multiple Myeloma Patients to Receive Outpatient Teclistamab (Part 1): Inclusion Criteria: 1. Eligible for teclistamab treatment as per Health Canada approved indication: 1. Age 18 and greater 2. Relapsed or refractory multiple myeloma 3. Received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody 4. Demonstrated disease progression on the last therapy 2. For Cohorts 1 and 2, participants must agree to receive treatment at Princess Margaret Cancer Centre. For Cohort 3, participants must agree to receive treatment at Stronach Regional Cancer Centre. 3. Must sign the informed consent form (or their legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study. Consent is to be obtained prior to the initiation of any study-related tests or procedures that are not part of standard of care